Episode 348
Liquid Biopsy Enables Precision Cancer Care: Bill Morice, M.D., Ph.D.
April 3, 202511m 9s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, invited Min-Han Tan, M.B.B.S., FRCP, Ph.D., founding CEO and medical director of Lucence, to discuss liquid biopsy cancer testing. Mayo Clinic Laboratories and Lucence recently announced a collaboration to expand access to this cutting-edge cancer test that is designed to detect clinically relevant biomarkers in ctDNA and ctRNA.
During their conversation, Dr. Morice and Dr. Tan explore:
- Inspiration for developing the liquid biopsy.
- Features that differentiate LiquidHALLMARK® from existing cancer tests.
- Patients who will benefit from the test and how an oncologist might use the results.
- The future potential of liquid biopsy advancements.
Topics
laboratory medicinehealthcareanswers from the labmayo clinic laboratorieslabmayo clinicclinicalDLMPMoricePritt